🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. pembrolizumab

    Hospital Authority, Hong Kong

    Locally Recurrent Cancer

    phase 2 small molecule active

    1 trial

  2. pemetrexed

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Brain Metastases

    phase 2 small molecule active

    1 trial

  3. penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

    The First People's Hospital of Lianyungang

    Lymphoma, Large B-Cell, Diffuse

    phase 2 small molecule active

    1 trial

  4. pharmorubicin or pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. placebo

    The First People's Hospital of Lianyungang

    COVID-19 Thalidomide

    phase 2 small molecule active

    1 trial

  6. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

    The First People's Hospital of Lianyungang

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  7. rabbit ATG, Cyclosporine, Levamisole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial

  8. radiation therapy

    Children's Hospital of Fudan University

    Brain Tumor

    phase 2 other completed

    1 trial

  9. raltitrexed combined with apatinib

    Chinese PLA General Hospital

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. real-tDCS with MI-BCI

    Hospital Authority, Hong Kong

    Stroke

    phase 2 other completed

    1 trial

  11. recombinant human endostatin

    Peking University Third Hospital

    Melanoma

    phase 2 small molecule active

    1 trial

  12. recombinant human erythropoietin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypoxic-Ischemic Encephalopathy

    phase 2 small molecule completed

    1 trial

  13. recombinant human erythropoietin (rhEpo)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Infant, Premature

    phase 2 small molecule active

    1 trial

  14. recombinant human growth hormone

    Affiliated Hospital of Jiangnan University

    Phelan-McDermid Syndrome

    phase 2 small molecule completed

    1 trial

  15. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  16. remicade (anti tumor necrosis factor inhibitor)

    Hospital Authority, Hong Kong

    Takayasu's Arteritis

    phase 2 small molecule active

    1 trial

  17. retinal pigment epithelium transplantation

    The First People's Hospital of Lianyungang

    Dry Age-related Macular Degeneration

    phase 2 mab active

    1 trial

  18. rhGM-CSF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Alveolar Proteinosis

    phase 2 small molecule active

    1 trial

  19. rituximab

    Children's Hospital of Fudan University

    Lymphoproliferative Disorder

    phase 2 mab completed

    1 trial

  20. rituximab /Dexamethasone/cyclophosphamide

    The First People's Hospital of Lianyungang

    Treatment

    phase 2 small molecule active

    1 trial

  21. sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  22. self-expandable 125I radioactive seeds-loaded-stent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocellular Carcinoma

    phase 2 other completed

    1 trial

  23. sintilimab

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  24. sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources